HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

oxeladin

RN given refers to parent cpd; structure

Also Known As:

2-(2-diethylaminoethoxy)ethyl 2-ethyl-2-phenylbutyrate; Paxéladine; Pectamol; Tussimol; oxeladin citrate

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Carboxylic Acids: 973
  - Carbocyclic Acids
    - Phenylbutyrates
      - oxeladin: 1

Related Diseases

1.	Stroke (Strokes) 09/13/2023 - "These results suggest that oxeladin may reduce the extent of infarct expansion in the subacute phase of stroke, although this action does not appear to involve a reduction in inflammation or increased cell proliferation." 09/13/2023 - "In this study, we hypothesized that oral oxeladin citrate would stimulate BDNF secretion and improve stroke outcomes when administered to male rats starting 48 h after transient middle cerebral artery occlusion. "
2.	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 09/13/2023 - "In this study, we hypothesized that oral oxeladin citrate would stimulate BDNF secretion and improve stroke outcomes when administered to male rats starting 48 h after transient middle cerebral artery occlusion. "
3.	Inflammation (Inflammations) 09/13/2023 - "These results suggest that oxeladin may reduce the extent of infarct expansion in the subacute phase of stroke, although this action does not appear to involve a reduction in inflammation or increased cell proliferation."
4.	Infarction (Infarctions) 09/13/2023 - "These results suggest that oxeladin may reduce the extent of infarct expansion in the subacute phase of stroke, although this action does not appear to involve a reduction in inflammation or increased cell proliferation."

Related Drugs and Biologics

1.	Brain-Derived Neurotrophic Factor (BDNF)